Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative cardiovascular medicines. The company's mission is to improve the lives of individuals with cardiovascular conditions by empowering them to self-manage their care. Headquartered in Montreal, Quebec, Canada, Milestone Pharmaceuticals focuses on creating treatment solutions that can be self-administered outside traditional emergency or healthcare settings.

The company's primary product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker. This product is approved for the acute treatment of paroxysmal supraventricular tachycardia (PSVT) in adults, offering the first self-administered treatment option for this condition. Milestone Pharmaceuticals is also advancing etripamil for other episodic cardiovascular conditions, including atrial fibrillation with rapid ventricular rate (AFib-RVR).

Milestone Pharmaceuticals achieved a significant milestone with the FDA approval of CARDAMYST™ (etripamil) nasal spray in December 2025, with the product becoming available in U.S. retail pharmacies in early 2026. In March 2026, Express Scripts added CARDAMYST™ to its commercial national formularies, expanding patient access. Led by President and CEO Joseph Oliveto, the company has transitioned from a development-stage biotechnology firm to a commercial-stage specialty pharmaceutical operator, emphasizing therapies that provide patients with an active role in managing their conditions.